SynthesisThe Lancet. Global health2021
Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study.
Synthesis in The Lancet. Global health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 617 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of New Defocus Spectacle Lens in Preventing Progression of Myopia Compared With the Conventional Single-vision Spectacle Lens: a Randomized Controlled Trial Among Chinese Children
Seeing to Learn in Sierra Leone: Impact of Spectacle Correction on Children's Academic Performance and Mental Health Wellbeing
Wearable Echolocation Aids Using Parametric Sound
Who cites it
617 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,289 citations in OpenAlex.
- Depression and Anxiety in Patients With Irreversible Vision Loss: Meta-Analysis and Systematic Review.International journal of psychiatry in medicine · 2026Pooled it
- Risk and protective factors associated with depressive symptoms in older adults with visual impairment: a systematic review.The Gerontologist · 2026Pooled it
- Image-Based Deep Learning for Cataract Diagnosis: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Effectiveness of low vision rehabilitation on visual function and quality of life in Sub-Saharan Africa: a systematic review.Frontiers in rehabilitation sciences · 2026Pooled it
- Depression and Depressive Symptoms in Glaucoma: A Systematic Review and Meta-Analysis of Comparative, Prevalence, and Longitudinal Evidence.Depression and anxiety · 2026Pooled it
- The impact of visual impairment and comorbid mental health disorders on daily functioning: a systematic literature review.BMC psychiatry · 2025Pooled it
- The prevalence of all stype of diabetes and pre‑diabetes in the Eastern Mediterranean countries: a meta‑analysis study.BMC endocrine disorders · 2025Pooled it
- Community-based interventions to detect visual impairment in community-dwelling older adults aged ≥ 75 years: a systematic review.BMC public health · 2025Pooled it
- Trial
- The effect of low vision rehabilitation on the quality of life and caregiver burden of low vision patients - a randomized trial.BMC ophthalmology · 2025Trial
- Advancements and challenges in ophthalmic microneedles to treat eye diseases.Drug delivery · 2026Review
- An injectable hydrogel for localized sustained release of artesunate in postoperative fibrosis prevention after glaucoma filtration surgery.Drug delivery · 2026Article
- Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities.Current therapeutic research, clinical and experimental · 2026Review
- Trends and disparities of vision impairment in Mexico from 1990 to 2023: a comparative analysis with Latin America and the Caribbean based on the Global Burden of Disease Study 2023.Lancet regional health. Americas · 2026Article
- Lactate-induced MBD2 K186 lactylation promotes YAP1-dependent myofibroblast-like remodeling of Müller cells in diabetic retinopathy.Molecular biomedicine · 2026Article
- Co-Designing Medication Safety Interventions for Community Pharmacy: Bringing Together People Living With Visual Impairments and Community Pharmacists Using a Modified Nominal Group Technique Approach.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Twelve-Year Incidence, Causes, and Determinants of Visual Impairment and Visual Improvement in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study.Ophthalmology science · 2026Article
- International Classification of Functioning, Disability and Health (ICF) Core Sets for Vision Loss: results of a Delphi consensus study.BMJ open ophthalmology · 2026Article
- Camera Configuration for Wearable Electronic Travel Aids Supporting Urban Mobility of Visually Impaired People.Sensors (Basel, Switzerland) · 2026Article
- Dietary and Formulation Potential of Natural Oils and Fats in Ocular Health and Disease: Mechanisms, Evidence, and Future Directions.Nutrients · 2026Review
557 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 20 institutions in 30 countries.
Funding
Abstract
backgroundTo contribute to the WHO initiative, VISION 2020: The Right to Sight, an assessment of global vision impairment in 2020 and temporal change is needed. We aimed to extensively update estimates of global vision loss burden, presenting estimates for 2020, temporal change over three decades between 1990-2020, and forecasts for 2050.
methodsWe did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. Only studies with samples representative of the population and with clearly defined visual acuity testing protocols were included. We fitted hierarchical models to estimate 2020 prevalence (with 95% uncertainty intervals [UIs]) of mild vision impairment (presenting visual acuity ≥6/18 and <6/12), moderate and severe vision impairment (<6/18 to 3/60), and blindness (<3/60 or less than 10° visual field around central fixation); and vision impairment from uncorrected presbyopia (presenting near vision <N6 or <N8 at 40 cm where best-corrected distance visual acuity is ≥6/12). We forecast estimates of vision loss up to 2050.
findingsIn 2020, an estimated 43·3 million (95% UI 37·6-48·4) people were blind, of whom 23·9 million (55%; 20·8-26·8) were estimated to be female. We estimated 295 million (267-325) people to have moderate and severe vision impairment, of whom 163 million (55%; 147-179) were female; 258 million (233-285) to have mild vision impairment, of whom 142 million (55%; 128-157) were female; and 510 million (371-667) to have visual impairment from uncorrected presbyopia, of whom 280 million (55%; 205-365) were female. Globally, between 1990 and 2020, among adults aged 50 years or older, age-standardised prevalence of blindness decreased by 28·5% (-29·4 to -27·7) and prevalence of mild vision impairment decreased slightly (-0·3%, -0·8 to -0·2), whereas prevalence of moderate and severe vision impairment increased slightly (2·5%, 1·9 to 3·2; insufficient data were available to calculate this statistic for vision impairment from uncorrected presbyopia). In this period, the number of people who were blind increased by 50·6% (47·8 to 53·4) and the number with moderate and severe vision impairment increased by 91·7% (87·6 to 95·8). By 2050, we predict 61·0 million (52·9 to 69·3) people will be blind, 474 million (428 to 518) will have moderate and severe vision impairment, 360 million (322 to 400) will have mild vision impairment, and 866 million (629 to 1150) will have uncorrected presbyopia.
interpretationAge-adjusted prevalence of blindness has reduced over the past three decades, yet due to population growth, progress is not keeping pace with needs. We face enormous challenges in avoiding vision impairment as the global population grows and ages.
fundingBrien Holden Vision Institute, Fondation Thea, Fred Hollows Foundation, Bill & Melinda Gates Foundation, Lions Clubs International Foundation, Sightsavers International, and University of Heidelberg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.